Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript

Roivant said its first quarter was relatively quiet operationally but positioned the company for a m

IMVT posts a wider quarterly loss as R&D spending rises, but its cash runway supports IMVT-1402 thro

All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves' d

I initiate coverage of Immunovant with a BUY rating and a $50 price target, driven by optimism aroun

NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is i

Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock?

IMVT shares climb as IMVT-1402 posts encouraging data, advances across autoimmune diseases and benef

Wall Street analysts changed outlook on top names. Guggenheim raised price target for IMVT, Piper Sa

Immunovant's underlying bull case has now moved away from batoclimab and toward IMVT-1402. This newe

Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbust

Immunovant Inc (NASDAQ:IMVT) on Wednesday posted a wider fourth‑quarter loss than analysts expected.

Immunovant stock jumps 35% as strong early IMVT-1402 data in rheumatoid arthritis boosts confidence

Immunovant Inc (NASDAQ:IMVT) shares are trading higher on Wednesday even though the company posted a

Roivant executives used the company's fourth-quarter and fiscal-year earnings call to highlight new

DURHAM, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage imm

DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it wil

Immunovant, Inc. (NASDAQ: IMVT - Get Free Report) CTO Jay Stout sold 2,754 shares of Immunovant stoc

Arcus Biosciences (NYSE: RCUS - Get Free Report) and Immunovant (NASDAQ: IMVT - Get Free Report) are

Immunovant slips 2.4% after batoclimab misses key phase III endpoints in thyroid eye disease trials,

Roivant Sciences and Priovant Therapeutics executives outlined an expansion of the brepocitinib deve

Dow futures down 400 points, Alto Neuroscience shares dip 13.6% after Phase 2 trial results, other s

Amazon may acquire Globalstar Inc., shares soared in pre-market trading. Other gainers include Turbo

  On Wednesday, 807 companies reached new 52-week lows.

Stocks That Hit 52-Week Lows On Wednesday

Stocks That Hit 52-Week Lows On Monday

Stocks That Hit 52-Week Lows On Thursday

Stocks That Hit 52-Week Lows On Wednesday

Stocks That Hit 52-Week Highs On Thursday

Stocks That Hit 52-Week Highs On Friday